Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selonsertib in Compensated Cirrhosis Due to NASH
NCT03053063Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of selonsertib in Nonalcoholic steatohepatitis (NASH), sponsored by Gilead Sciences. Started Jan 2017; status: terminated.
02
Drugs
selonsertib
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03053063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053063.